Physician profile
Stuart Barr
NPI 1992700579
$2,588.17
in general payments reported to CMS, 2019-2025
20 companies · $36.19 in 2025
The $36.19 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $208 · 2021: $376 · 2022: $972 · 2023: $330 · 2024: $259 · 2025: $36.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $559.33 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $286.94 | 2019-2025 | Watchman Access System, Watchman Flx |
| Amgen INC. | $274.39 | 2019-2023 | Repatha |
| Medtronic, INC. | $216.59 | 2022-2023 | Appose Ulc |
| Abbott Laboratories | $201.15 | 2022-2024 | Cardiomems |
| Edwards Lifesciences Corporation | $197.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $168.04 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $136.07 | 2019-2025 | Camzyos, Eliquis |
| Asensus Surgical, INC. | $119.71 | 2022-2023 | Senhance |
| Alnylam Pharmaceuticals INC. | $113.76 | 2019 | |
| Pfizer INC. | $85.85 | 2019-2021 | |
| Amarin Pharma, INC. | $55.27 | 2019-2021 | |
| Novo Nordisk INC | $35.49 | 2024 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.07 | 2022-2023 | Jardiance |
| Esperion Therapeutics, INC. | $29.06 | 2022-2024 | Nexletol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $18.74 | 2023 | Zio Xt Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.02 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.48 | 2020 | |
| Merck Sharp & Dohme LLC | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.